Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Microbot Medical Inc (NQ: MBOT )

0.9800 +0.0503 (+5.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Microbot Medical Inc

< Previous 1 2 3 Next >
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company’s robust quality system 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
Following the Company’s recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k)... 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Shares Status Following Recent Geopolitical Events
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
From Microbot Medical Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.